Back

Combination therapy with macitentan and phosphodiesterase type-5 inhibitor (PDE5i) in pulmonary arterial hypertension (PAH): real-world data from OPUS and OrPHeUS

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)

62 More presentations in this session

Presentation thumbnail
Shift in transcriptional landscape of human right ventricle in chronic thromboembolic pulmonary arterial hypertension
Ms L. Jafari (Giessen, DE)
Abstract Slides
Presentation thumbnail
Relationship between right ventricular diastolic dysfunction, right atrial phasic function and ventricular filling in pulmonary arterial hypertension
Mr J. Wessels (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Aetiology of sarcoidosis-associated pulmonary hypertension
Mr H. Mathijssen (Nieuwegein, NL)
Abstract Slides
Presentation thumbnail
Pre-operative pulmonary artery pulsatility index does not predict mortality post cardiac transplantation but PVR is a prognostic tool in LVAD-bridged patients.
Doctor N. Bart (Boston, US)
Abstract Slides
Presentation thumbnail
Venous lactate predicts adverse outcomes in normotensive pulmonary embolism
Doctor M. Ebner (Wien, AT)
Abstract Slides

Access the full session

Session thumbnail
Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: Insights from the randomised controlled TRITON study
29 August 2020
thumbnail
Congress Presentation
Safety and efficacy of sildenafil in patients with advanced heart failure.
22 May 2023
thumbnail
Congress Presentation
Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: Real-world data from OPUS and OrPHeUS
29 August 2022
thumbnail
Congress Presentation
Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry)
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources